Details for Patent: 10,765,602

Which drugs does patent 10,765,602 protect, and when does it expire?

Patent 10,765,602 protects BAQSIMI and is included in one NDA.

This patent has seventeen patent family members in eleven countries.

Summary for Patent: 10,765,602

Title:	Medication delivery systems and methods
Abstract:	The present disclosure relates to a medication delivery system including a medication administration device, a medication within the medication administration device, a container defining a cavity receiving the medication administration device, and a cap attached to the container and sealing the medication administration device within the cavity. The medication administration device includes an actuator extending from a body and operable to expel the medication by depressing the actuator into the body. The cap includes hold down members positioned to bear against the body of the medication administration device to prevent movement of the medication administration device toward the cap beyond a predetermined distance. The medication administration device is thereby prevented, inter alia, from prematurely discharging the medication during storage and transport.
Inventor(s):	Arnett; Jaime Ray (Fishers, IN), Snow; Andrew Thomas (Fishers, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	16/578,498
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Device;

Drugs Protected by US Patent 10,765,602

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amphastar Pharms Inc	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019		RX	Yes	Yes			Y

International Family Members for US Patent 10,765,602

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019438995
Canada	3130823
China	113613671